GlassScriptPhysician profile
Kathryn L Grant
NPI 1417040098
$1,931.21
in general payments reported to CMS, 2019-2025
19 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $502 · 2023: $354 · 2024: $267 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.42 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $548.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $199.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.11 | 2021-2022 | |
| Seagen INC. | $122.67 | 2021 | |
| Mirati Therapeutics, INC. | $120.29 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $119.77 | 2021-2024 | Qinlock |
| Celgene Corporation | $114.04 | 2022-2024 | Reblozyl |
| Gilead Sciences, INC. | $100.14 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $83.37 | 2023-2025 | |
| Abbvie INC. | $69.59 | 2024-2025 | |
| Hologic Sales and Service, LLC | $53.60 | 2024-2025 | Aptima |
| Pfizer INC. | $51.15 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $41.64 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.21 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.20 | 2023 | Imbruvica |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.94 | 2022 | |
| Merck Sharp & Dohme LLC | $18.15 | 2025 | Reblozyl |
| Beone Medicines USA, INC. | $16.10 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.